News Contact Us

Janssen begins phase 3 trials of its potential COVID-19 vaccine in U.K.

Author : Pankaj Singh | Published Date : 2020-11-17 

According to reliable sources, Belgium-based multinational pharmaceutical company, Janssen Pharmaceutica has reportedly initiated the administration and enrolment of participants for the phase 3 clinical trials of its potential COVID-19 vaccine candidate.

If sources are to be believed, the investigational drug, which is modelled on the Ebola vaccine, will be initially tested on 6000 participants from 17 locations across the United Kingdom including Southampton, Leicester, Dundee, Cardiff, Bristol and Belfast. Moreover, a total of 24,000 volunteers will be recruited from other countries.

For the record, the placebo-controlled trials will investigate the efficacy and safety of the potential coronavirus vaccine by introducing a weakened common cold virus. The virus will apparently spike the coronavirus proteins in the cells of the candidates, which will in turn trigger an immune response.

It is to be noted that the phase 1 and 2 trials of Janssen’s vaccine revealed that the investigational drug induces a robust immune response and is well-tolerated by a majority of the candidates.

Sources close to the matter claimed that around 25,000 Britons have participated in the clinical trials for the potential COVID-19 vaccine and more than 310,000 individuals have agreed to sign up to the NHS (National Health Service) vaccine research registry.

Chairman of the U.K. vaccine taskforce, Kate Bingham was reported saying that although the recent development is highly encouraging, the department will continue to focus towards the research of the safety and efficacy of COVID-19 vaccine.

Saul Faust, principal investigator of the clinical trials and professor of pediatric immunology and infectious diseases at the University of Southampton mentioned in a statement that there is a high demand for volunteers who are at a great risk for contracting the Coronavirus, primarily frontline health and social care workers and individuals from the Asian, African and other minority communities.

If the phase 3 trials conclude the efficacy and safety of the investigational vaccine, the U.K. government will reportedly administer around 30 million doses of the drug by the first half of 2021.

Source credits: https://www.theguardian.com/world/2020/nov/16/6000-uk-volunteers-to-be-injected-with-covid-vaccine-in-phase-3-trial

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

SpaceX sees 500,000 Starlink pre-bookings, launches 60 more satellites

Published Date: 2021-05-06         Author: Pankaj Singh

American aerospace manufacturer and space transportation services company SpaceX, reportedly, on Tuesday added 60 more Starlink internet broadband satellites to its constellation, only five days after it got its last batch into the orbit. The launch, initiated from Cape Canaveral in Florida, util... Read More

Tyson Foods takes on Beyond Meat with new plant-based meat lineup

Published Date: 2021-05-05         Author: Pankaj Singh

Tyson Foods Inc is reportedly introducing new plant-based hamburgers and sausages, adding to the competition for Beyond Meat, which is launching an improved version of its faux burger. Plant-based meat producers expect an increase in revenue as COVID-19 vaccines encourage more people to eat out a... Read More

Trifork acquires Swiss IT firm Vilea to fortify its presence in Europe

Published Date: 2021-05-04         Author: Pankaj Singh

Trifork Holding AG, a company that specializes in providing advanced IT and business services, has reportedly acquired Swiss-based IT firm Vilea. The move will allow Trifork to expand its service reach in Switzerland and reinforce its presence in Europe. Founded in 2009, Vilea has emerged as a pr... Read More

© 2021 Fractovia. All Rights Reserved